<span item_type="fundamental" item_id="5142ef6c53669d50fffd7d59e2a09bed" counter_id="ST/US/SIMAW" env="prod"></span><span item_type="announcement" item_id="582435114921101057" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.07.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.768 M.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and will not generate operating revenues until after the completion of its Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the three months ended September 30, 2025, net income was $2,252,165, which includes $2,510,176 of interest income earned on the Trust Account, offset by $258,011 of general and administrative costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li><li>For the nine months ended September 30, 2025, net income was $6,772,463, which includes $7,453,481 of interest income earned on the Trust Account, offset by $681,018 of general and administrative costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025 was - $527,940.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li><li>Cash at the end of the period was $169,145.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Interest earned on cash and marketable securities held in the Trust Account for the nine months ended September 30, 2025 was $7,453,481.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>The company intends to effectuate its initial Business Combination using cash from the proceeds of the Initial Public Offering and the Private Placement, among other financing methods.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li><li>The company has until July 11, 2026 to consummate a Business Combination, failing which there will be a mandatory liquidation and subsequent dissolution.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company may pursue an initial Business Combination in any business or industry, but is focusing on companies in the healthcare industry.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul><h3>Priority</h3><ul><li>The company has substantial doubt about its ability to continue as a going concern due to the mandatory liquidation and subsequent dissolution if a Business Combination is not consummated by July 11, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2014982/000121390025109984/ea0264564-10q_simacq1.htm"></span></li></ul>

SIM ACQUISITION CORP. I WTS 01/06/31 (TO SUB FOR ORD) | 10-Q: FY2025 Q3 Revenue: USD 0